Christopher Hoimes
@DrChrisHoimes
Oncologist. Investigator. ImmunoOncology, biomedical engineering, phase I, #bladdercancer #prostateCa #renal #melanoma
ID:1163683343151575041
20-08-2019 05:25:13
58 Tweet
291 Takipçi
429 Takip Edilen
Huge honor to chair John Quale Travel Fellow Awards & moderate this session with amazing rising ⭐️ Ali Khaki Carissa Chu Nate Brooks Rich Matulewicz Jeffrey Wong John Christin!As Matt Galsky said:future is bright! Bladder Cancer Advocacy Network Christopher Hoimes Sima Porten Stephanie Chisolm, PhD OncoAlert
Updated Society for Immunotherapy of Cancer (SITC) clinical practice guidelines on #immunotherapy for the treatment of #bladdercancer out today
dx.doi.org/10.1136/jitc-2…
#SITCGuidelines #BladderCancer Journal for ImmunoTherapy of Cancer UroToday.com Bladder Cancer Advocacy Network IBCG IBCN
Enfortumab Vedotin now approved U.S. FDA for post PD1 setting! - regardless of prior platinum- in pts with metastatic UC, cis- ineligible
👏🏻based on EV201-c2 +301 Arjun Balar MD Daniel Petrylak Bradley McGregor Jonathan Rosenberg MD Andrea Necchi Michael Harrison Tian Zhang, MD, MHS Dan George
Enfortumab Vedotin FULL approval U.S. FDA for patients with metastatic urothelial cancer previously treated with platinum and anti-PD-1/PD-L1!
EV201-c1 and EV301: EV v taxane: HR 0.70, mOS 12.9 v 9 mo, 80% had visceral dz, 70% had PD on PD1 Jonathan Rosenberg MD businesswire.com/news/home/2021…
Congratulations Christian! Bausch + Lomb science is officially a Hoimes family tradition! Thank you Chagrin Schools teachers for your commitment to challenge and inspire Lisa Salyers @MonicaJAsherED Amanda Rassi Brittany Anderson Laseak @cfdeighan Dr. Robert Hunt
#IBCN2019 Muscle-invasive #BladderCancer novel mouse model capable of orthotopic transplantation. Presentation by Dr. John Sfakianos Icahn School of Medicine at Mount Sinai. Written coverage by Vikram M. Narayan, MD and Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center on UroToday > bit.ly/2VJBBB8 IBCN
Congratulations to Yale Cancer Center Peter Glazer and Mark Saltzman, and Carnegie Mellon University Danith Ly, who received a new NIH grant to advance a novel genome-editing technology into patient care. Yale New Haven Health Yale Medicine @Yale
cmu.edu/mcs/news-event…
#IBCN2019 bladder cancer round table discussion underway with Andrea Necchi moderator and all star line up Gottfrid Sjödahl Ewan Gibb William Y. Kim Michiel van der Heijden
Eric Jonasch With promising 80% disease control rate w 24% ORR for HIF inhibitor from Peloton, in refractory metastatic #RCC . More anemia but less diarrhea, HFS, and mucositis compared to VEGF inhibitors. #ESMO19 #oncoalert
“Researchers knew that XPO1 regulates which proteins are located in a cell’s nucleus & which get moved to the cytoplasm. But until now, nobody has ever shown how the alteration of the XPO1 protein could cause cancer. This study shows how.” Abdel-Wahab Lab bit.ly/2mBwqWt
Augmented Bladder Tumor Detection Using Deep Learning
Eugene Shkolyar
#VisualAbstract
europeanurology.com/article/S0302-…
'Nonmetastatic' Castration-Resistant Prostate Cancer is now officially a misnomer. New research in patients with normal CT and bone scans, show almost 100% PSMA PET+, 55% with M1 disease. clincancerres.aacrjournals.org/content/early/… GU Cast | Urology podcast!
Single Lesion on PSMA-ligand PET and Low PSA Are Prognostic Factors for a Favorable Biochemical Response to PSMA-targeted Radioguided Surgery in Recurrent #ProstateCancer
#VisualAbstract
buff.ly/2GBeMsg
Thrilled that our lab’s super cool work on endogenous retrovirus-derived immunogenic peptides in cancer is finally out in Genome Research! genome.cshlp.org/content/early/…
... and Kidney Cancer Assn Young Investigator Award winner for work in #renalcancer #immunotherapy
Dr Tian Zhang. Tian Zhang, MD, MHS bit.ly/2ZGHiUZ
- Oncologist for GU malignancies, partnering with Urology, RadOnc
- PI on multiple studies examining immunotherapies, and also the #PDIGREE trial for metastatic #RCC
#WIMMonth #DukePWIM #MedTwitter Duke Department of Medicine Duke Cancer
